Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project
Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Janssen Pharmaceuticals, Titusville, New Jersey, USA.
Department of Internal Medicine and Institute for Clinical Immunology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany.
Show others and affiliations
2021 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 11, no 4, article id e045851Article in journal (Refereed) Published
Abstract [en]

Introduction

Amidst growing consensus that stakeholder decision-making during drug development should be informed by an understanding of patient preferences, the Innovative Medicines Initiative project ‘Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle’ (PREFER) is developing evidence-based recommendations about how and when patient preferences should be integrated into the drug life cycle. This protocol describes a PREFER clinical case study which compares two preference elicitation methodologies across several populations and provides information about benefit–risk trade-offs by those at risk of rheumatoid arthritis (RA) for preventive interventions.

Methods and analysis

This mixed methods study will be conducted in three countries (UK, Germany, Romania) to assess preferences of (1) first-degree relatives (FDRs) of patients with RA and (2) members of the public. Focus groups using nominal group techniques (UK) and ranking surveys (Germany and Romania) will identify and rank key treatment attributes. Focus group transcripts will be analysed thematically using the framework method and average rank orders calculated. These results will inform the treatment attributes to be assessed in a survey including a discrete choice experiment (DCE) and a probabilistic threshold technique (PTT). The survey will also include measures of sociodemographic variables, health literacy, numeracy, illness perceptions and beliefs about medicines. The survey will be administered to (1) 400 FDRs of patients with RA (UK); (2) 100 FDRs of patients with RA (Germany); and (3) 1000 members of the public in each of UK, Germany and Romania. Logit-based approaches will be used to analyse the DCE and imputation and interval regression for the PTT.

Ethics and dissemination

This study has been approved by the London-Hampstead Research Ethics Committee (19/LO/0407) and the Ethics Committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg (92_17 B). The protocol has been approved by the PREFER expert review board. The results will be disseminated widely and will inform the PREFER recommendations.

Place, publisher, year, edition, pages
BMJ BMJ Publishing Group Ltd, 2021. Vol. 11, no 4, article id e045851
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:uu:diva-439954DOI: 10.1136/bmjopen-2020-045851ISI: 000639385400003OAI: oai:DiVA.org:uu-439954DiVA, id: diva2:1543649
Projects
IMI-PREFERAvailable from: 2021-04-12 Created: 2021-04-12 Last updated: 2024-01-15Bibliographically approved

Open Access in DiVA

fulltext(519 kB)256 downloads
File information
File name FULLTEXT01.pdfFile size 519 kBChecksum SHA-512
8169615dd5e4bbdb45306e36a229e9a711396c1fddd44554dd7782a0eb52ca32d25da5e774e09dd94172ecf7a3e72e5719a0aa9da38b258f8549f48f2e2da961
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records

Schölin Bywall, KarinKihlbom, Ulrik

Search in DiVA

By author/editor
Schölin Bywall, KarinKihlbom, Ulrik
By organisation
Centre for Research Ethics and Bioethics
In the same journal
BMJ Open
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar
Total: 261 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 253 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf